BioMarin Announces Second Quarter 2015 Financial Results and Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Wedbush Raises Price Target on BioMarin Pharma (BMRN) to $139 Following 2Q Results
August 5, 2015 6:44 AM EDTWedbush reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $139.00 (from $130.00), following Q2 earnings. Q2 revenues of $250.5MM beat consensus ($218.2MM). GAAP-EPS of $(0.55) was below consensus of $(0.53) due to high Op-Ex.
Analyst Liana Moussatos commented, "Q2... More
Piper Jaffray Raises Price Target on BioMarin Pharma (BMRN) to $168 Following 2Q Results
August 4, 2015 8:41 AM EDTPiper Jaffray reiterated an Overweight rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $168.00 (from $163.00), following 2Q15 earnings results. Analyst Joshua Schimmer said that the results beat top and bottom line driven primarily by lumpy Naglazyme purchasing and reiterated... More
